Reactions Weekly

, Volume 1734, Issue 1, pp 113–113 | Cite as

Carfilzomib/doxorubicin liposomal

Various toxicities: 4 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a single-centre, retrospective case-series of 32 patients conducted between June 2014 and June 2016, four patients including one man and two women [not all ages and sexes stated] were described, who developed infusion related reactions, new-onset atrial flutter, palpitations or acute heart failure exacerbation during treatment with carfilzomib (2 patients) and carfilzomib and doxorubicin (2 patients) [indications and outcomes not stated; not all routes, dosages and durations of treatments to reactions onsets stated]. The dosages of carfilzomib were ranged between 27−56 mg/m2 and was off label.

This report describes the patient who received five infusions of carfilzomib for 20-minute each. Eventually, the patient switched to 30-minute infusions and developed infusion related...


  1. Kim GY, et al. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m2: A case series. Journal of Oncology Pharmacy Practice 25: 229-233, No. 1, Jan 2019. Available from: URL: - USACrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations